baber/WOPTO huggingface dataset:
Patent AU-774311-B2 (AU)
Title: Method and system for producing customized cosmetic and pharmaceutical formulations on demand
Inventor: AUST DUNCAN T
IPC: G06Q30/00
Filed: 2001-01-31
Granted: 2004-06-24
Abstract: A method and system for selecting and producing a customized cosmetic or pharmaceutical formulation is disclosed below. The system can be implemented in an Internet based system or a stand-alone version, such as a Kiosk. An improved method of custom formulation is presented which utilizes the user's preferences and profile, as well as external factors. The customized formulation can be directed to a manufacturing facility for on-demand production. Alternatively, a printout of the formulation can be provided for subsequent use at point-of-sale locations, such as a cosmetics store or a pharmacy. The custom formulation software can also be provided in conjunction with a cosmetics manufacturing kit for use in home or business application.
Patent AU-669877-B2 (AU)
Title: Device for granulating plastics
Inventor: BACHER HELMUT
IPC: B29K27/00
Filed: 1993-02-10
Granted: 1996-06-27
Abstract: Proposed is a device for granulating thermally unstable plastics, the device having a plasticizing screw (13) which is located in a housing (14) and is tip-driven  by a drive unit (12). The plasticizing screw (13) conveys the plastic material through outlet ports (27) over which at least one granulating blade (29) which is driven to rotate by a drive unit (7) passes. The drive unit (12) for the plasticizing screw (13) is located at the same end of the screw as the oulet ports (27), the path of the granulating blade (29) passing between this drive unit (12) and the outlet ports (27). The drive shaft (15) for the plasticizing screw (13) is designed as a separate component from the screw and is rotatably and detachably coupled to the end of the screw (13). Air from a blower (10) is used to cool and remove the plastic granules cut off by the blade.
Patent AU-772669-B2 (AU)
Title: Process for the inactivation of viruses
Inventor: SCHULER ECKHARD
IPC: C07K1/36
Filed: 2000-05-18
Granted: 2004-05-06
Abstract: A process (I) for the treatment of a plasma protein solution to inactivate and/or eliminate enveloped and/or nonenveloped viruses comprising precipitating viruses with an ammonium salt, is new. A process (I) for treating a plasma protein solution to inactivate and/or eliminate enveloped and/or nonenveloped viruses comprises: (a) incubating the solution with 13-22 wt.% of an ammonium salt at room temperature and alkaline pH; (b) removing the precipitate; (c) removing the ammonium salt to reduce the residual ammonium salt concentration to less than 0.5 mole/liter; (d) pasteurizing the solution at about 60 degrees C for several hours; and (e) processing the solution to obtain a therapeutically usable plasma protein preparation. Independent claims are also included for the following: (1) a process (II) for treating a plasma protein solution to inactivate and/or eliminate enveloped and/or nonenveloped viru comprising: (a) incubating the solution with 13-22 wt.% of an ammonium salt at room temperature and alkaline pH; (b) removing the precipitate; (c) increasing the ammonium salt concentration to 24-27 wt.%; (d) incubating the solution again; (e) collecting the resulting virus-free precipitate; (f) removing the ammonium salt to reduce the residual ammonium salt concentration to less than 0.5 mole/liter; (g) pasteurizing the precipitate at about 60 degrees C for several hours; and (h) processing the precipitate to obtain a therapeutically usable plasma protein preparation; and (2) a plasma protein preparation obtainable by process (I) or (II).
Patent AU-665414-B2 (AU)
Title: Tetrahydrophthalamide derivative, intermediate for producing the same, production of both, and herbicide containing the same as active ingredient
Inventor: HIRAI KENJI
IPC: C07D295/185
Filed: 1993-03-25
Granted: 1996-01-04
Abstract: A 3,4,5,6-tetrahydrophthalamide derivative and a 3,4,5,6-tetrahydroisophthalimide derivative, both having an excellent efficay as the active ingredient of a herbicide, and an industrial process for efficiently producing these higher-performance, herbicidally active compounds. A tetrahydrophthalamide derivative represented by general formula (I) is produced by the reaction of a tetrahydrophthalimide derivative, prepared by the reaction of a halogenated 5-cycloalkyloxyaniline derivative with 3,4,5,6- tetrahydrophthalic anhydride, or of the tetrahydroisophthalimide derivative of the invention with various amines. These tetrahydrophthalamide and tetrahydroisophthalimide derivatives have an excellent herbicidal effect in the treatment of lowland and upland soils and foliage treatment. The tetrahydroisophthalimide derivative is useful also as an intermediate for producing the tetrahydrophthalamide derivative and the like. <CHEM>
Patent AU-772923-B2 (AU)
Title: Antithrombotic agents
Inventor: ASIM KANTI DUTTA-ROY
IPC: A23L19/00
Filed: 1999-04-23
Granted: 2004-05-13
Abstract: The invention provides a unit dosage form such as a tablet, lozenge, capsule, powder, granulate or gel, the unit dosage form containing an aqueous extract of tomato in a dried form, the aqueous extract having been prepared by homogenising the flesh of a tomato and removing solids therefrom. The unit dosage form contains a water soluble active fraction which is colourless or straw coloured and has platelet aggregation inhibitory activity. <IMAGE>
Patent AU-628868-B2 (AU)
Title: Grafted block copolymers, process for their manufacture and use of these copolymers
Inventor: KRANTZ NICHOLAS
IPC: C08L101/00
Filed: 1989-10-16
Granted: 1992-09-24
Abstract: The invention is in the field of plastics and relates to grafted block copolymers. Another subject of the invention is the synthesis of these grafted block copolymers. They are obtained by grafting and radical polymerisation of a monomeric composition on backbone-polymers whose units exhibit a block distribution. The invention also relates to the use of these grafted block copolymers are blend emulsifying agents and their use for the manufacture of moulded or extruded articles, films, sheets, etc.
Patent AU-692033-B2 (AU)
Title: Imidazo{4,5-c}quinoline amines
Inventor: LINDSTROM KYLE J
IPC: C07D471/14
Filed: 1995-12-06
Granted: 1998-05-28
Abstract: Compounds and pharmaceutically acceptable salts thereof formally derived by bridging the 1- and 2-positions of 1H-imidazo[4,5-c]quinolin-4-amines. Also, methods of using such compounds and pharmaceutical formulations containing such compounds. Said compounds are useful to induce interferon biosynthesis in an animal.
Patent AU-664640-B2 (AU)
Title: Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
Inventor: DIANA GUY DOMINIC
IPC: A61K31/505
Filed: 1993-08-31
Granted: 1995-11-23
Abstract: Compounds of the formula <CHEM>  wherein     R1 is selected from <CHEM>     R2 and R3 are independently hydrogen, lower-alkyl or halogen;     R4 is <CHEM>       R5 is hydrogen, lower-alkyl or halogen;     R6 is hydrogen, lower-alkyl or halogen;     R7 is hydrogen or lower-alkyl;     R8 is hydrogen, lower-alkyl, or trifluoromethyl;     R9 is lower-alkyl;     R10 is lower-alkyl, difluoromethyl or triifluoromethyl; and     Y is a bond or lower alkylene; or pharmaceutically acceptable acid addition salts thereof are useful as antiviral agents.
Patent AU-772872-B2 (AU)
Title: Improved trailer-mounted atomizer
Inventor: SMERALDI PAOLO
IPC: B62D49/06
Filed: 2000-05-31
Granted: 2004-05-13
Abstract: In a trailer-mounted atomizer, preset to be towed with a tractor (2) and including a spreading apparatus (1) fed from a tank (3) and a trailer (4) with a towing drawbar (5), the tank (3) is fixed directly onto the trailer (4), and the towing drawbar (5) of the trailer (4) is articulated to the tractor (2) by way of the spreading apparatus (1), this latter being removably fixed to the tractor (2).
Patent AU-681350-B2 (AU)
Title: Inhibitiion of retrovirus infection
Inventor: EISENBERG STEPHEN
IPC: A61K38/00
Filed: 1993-09-09
Granted: 1997-08-28
Abstract: Methods and pharmaceutical compositions are provided to prevent retroviral infections of host cells. More particularly, the invention relates to prevention of HIV infection of human cells by serine leukocyte protease inhibitor (SLPI).
Patent AU-582802-B2 (AU)
Title: Joint coupling of telescopic type, for adjusting the trajectory angle in sprinklers in general, and a sprinkler provided with said joint coupling
Inventor: DRECHSEL ARNO
IPC: F16L43/00
Filed: 1985-11-22
Granted: 1989-04-13
Abstract: A joint coupling comprises two pipe pieces (1), (5), which are in constant mutual communication and are partly inserted one into the other by way of respective curved portions (4,6) under fluid-tight engagement, said curved portions (4,6) being arranged for swivelling about a common axis (12) situated external to the joint coupling and containing the common centre of curvature of said curved portions (4,6). Means (13, 14, 15) are provided for locking/releasing the pipe pieces (1,5).
Patent AU-617933-B2 (AU)
Title: Aqueous preparation of pyrido {1,2-a}pyrimidine compound
Inventor: YAZAKI TAKASHI
IPC: A61K47/00
Filed: 1990-03-19
Granted: 1991-12-05
Abstract: An aqueous preparation comprising 0.1 to 0.3 % (W/V) of a pyrido[1,2-a]pyrimidine compound represented by the following formula I: <CHEM> (wherein R represents an n-propyl or allyl group; A A represents a tetrazolyl or carboxyl group; and n n represents an integer of 0 to 2), 0.5 to 2.0 % (W/V) of a polyoxyethylene sorbitan fatty acid ester, 0.5 to 2.0 % (W/V) of polyethylene glycol and 1.0 to 3.5 % (W/V) of disodium hydrogenphosphate.
Patent AU-729041-B2 (AU)
Title: Compositions containing perfume
Inventor: NESS JEREMY NICHOLAS
IPC: D06M15/263
Filed: 1997-12-23
Granted: 2001-01-25
Abstract: Perfume is absorbed within organic polymer particles which have a further polymer at their exterior. The further polymer incorporates free hydroxyl groups and serves to promote deposition of the particles from a wash or rinse liquor. The further polymer may be part of an encapsulating shell, but more conveniently is used as a stabilizer during polymerization of the particles. Highly hydrolyzed polyvinyl alcohol is preferred.
Patent AU-588574-B2 (AU)
Title: Stabilization of 5-chloro-3-isothiazolones
Inventor: AMICK DAVID RICHARD
IPC: A01N43/80
Filed: 1986-03-03
Granted: 1989-09-21
Abstract: 5-Chlor-3-isothiazolones are stabilized against chemical decomposition in non-aqueous solution using organic hydroxy solvent and, optionally, stabilization salt when the contents of the components are 0.5 to 10% isothiazolone, 89 to 99.5% hydroxy solvent and 0 to 1% stabilization salt, the percentages being by weight of the three stated components, the hydroxy solvent comprising one or more solvents of the formulae: <CHEM> wherein R and R<1> are hydrogen or lower alkyl, X is -CH2OCH2-or -(CH2)n- wherein n is an integer of 1 to 4 and y is an integer of 1 to 150. These compositions exhibit biocidal and preservative properties.
Patent AU-538517-B2 (AU)
Title: Power supply apparatus
Inventor: BRAKUS BOGDAN
IPC: H02M3/335
Filed: 1980-01-22
Granted: 1984-08-16
Abstract: 1. A circuit arrangement for regulating the output voltage of a single pulse flow converter having a free-running diode (D2) and a choke (L) connected thereto in the main circuit, and comprising an electronic switch (Ts) whose switching path is arranged between the input and output of the converter, and comprising a control device connected preceding the control path of the electronic switch (Ts), contains a bistable fli-flop (K) and serves to control the pulse width, where the bistable flip-flop (K) can be set by timing pulses (T) of a pulse generator and reset by disconnecting pulses which are transmitted by a threshold switch (S) which is controlled by measured variables and contains a comparison voltage source (UREF ), characterized in that the capacitor (Cv ) of a series capacitor-resistor combination (Cv , Rv ) connected at the output (a, b) of the converter, and a comparison voltage source (UREF ) are connected to the same terminal of the output (a, b), (a in Figure 1 ; b in Figure 2), which forms a reference point, that the terminal of the capacitor (Cv ) carrying voltage in comparison to the reference point is coupled to the measured variable input (-) by means of a voltage divider (RT1 , RT2 ) and the terminal of the chocke (L) connected to the free-running diode (D2) is led to the measured variable input (-) of the threshold switch (S) by means of a further resistor (RD ), that the resistance (RT2 ) of the voltage divider (RT1 , RT2 ) arranged between the voltage-carrying terminal of the capacitor (Cv ) and the threshold switch (S) is brigged by a capacitor (CD ) whose capacitance is dimensioned so as to be considerably smaller than the capacitance of the capacitor (C) of the series capacitor-resistor combination, and that the value of the resistance (Rv ) of the series capacitor-resistor combination (Cv , Rv ) is dimensioned to be essentially smaller, in particular by at least one order of magnitude, than the value of the resistance (RT1 , RT2 ) of the voltage divider.
Patent AU-695667-B2 (AU)
Title: Purification of roaster gases
Inventor: FELIP DOMINGO ARGILES
IPC: A23F5/04
Filed: 1996-05-08
Granted: 1998-08-20
Abstract: PCT No. PCT/EP96/01903 Sec. 371 Date Feb. 21, 1998 Sec. 102(e) Date Feb. 21, 1998 PCT Filed May 8, 1996 PCT Pub. No. WO96/35335 PCT Pub. Date Nov. 14, 1996A process for operating a coffee roaster to obtain reduced levels of pollutants in exhaust gases vented from the coffee roaster. In the process, fuel gases are combusted in a combustion chamber and all of the combusted gases are directed into a roasting chamber for roasting coffee beans in the roasting chamber. The exhaust gases from the roasting chamber are then separated into a recycle stream and an exhaust stream with the recycle stream comprising the majority of the exhaust gases. The recycle stream is returned to the combustion chamber. The exhaust stream is then subjected to secondary combustion at relatively low temperatures prior to venting.
Patent AU-723255-B2 (AU)
Title: Method of establishing the optimal radiation dose for radiopharmaceutical treatment of disease
Inventor: WAHL RICHARD L
IPC: A61N5/10
Filed: 1996-05-03
Granted: 2000-08-24
Abstract: A method for determining the number of millicurie to be administered to a patient so as to deliver a given centigray (cGy) dose of either the patient's lean body of the patient's total body. The method includes the steps of injecting a radioactive tracer into a patient, determining radiation levels in the whole body, calculating a geometric mean based on the radiation levels, determining the percent-injected activity remaining in the body at each time point, plotting the percent-injected activity versus calculated time from infusion on a log-linear graph, determining the effective half-life and the rate of clearance from the log-linear graph, cross-indexing the effective half-life vlue with the patient's body weight, and multiplying the determined amount of therapeutic millicurie per centigray by the amount of desired centigray to be administered.
Patent AU-633347-B2 (AU)
Title: Device for the continuous casting of thin metal products between rolls
IPC: B22D11/06
Filed: 1990-08-23
Granted: 1993-01-28
Abstract: The subject of the invention is an installation for the continuous casting of thin metal products between two cooled rotating rolls, of the type comprising a riser, called a "header", interacting with the rolls and the small faces in order to define the casting space, wherein the longitudinal walls of the header in contact with the rolls consist of a refractory with high heat-insulating properties and the front walls of the header in contact with the small faces consist of a refractory material with high mechanical strength.
Patent AU-772649-B2 (AU)
Title: Recombinant newcastle disease virus RNA expression systems and vaccines
Inventor: GARCIA-SASTRE ADOLFO
IPC: C12N7/01
Filed: 1999-09-14
Granted: 2004-05-06
Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.
Patent AU-724604-B2 (AU)
Title: Method of cleaning surfaces
Inventor: GROSCHL ANDREAS
IPC: C11D1/14
Filed: 1998-01-03
Granted: 2000-09-28
Abstract: A method of cleaning surfaces made of glass, graphite, ceramics, polymeric and metallic materials, synthetic and vegetable fibres, e.g. fabrics, textiles or waste paper, in particular membrane surfaces, by detaching or dissolving organic and inorganic soilings by a simple flushing operation, where a solution of an iminocarboxylic acid, a polyamino acid, an emulsifier or a mixture thereof is used.
Patent AU-676894-B2 (AU)
Title: Benzothiazole compound, process for producing the same, and use thereof
Inventor: HASE TAKEMA
IPC: C07D277/64
Filed: 1994-03-25
Granted: 1997-03-27
Abstract: A benzothiazole compound represented by general formula (I) and a pharmaceutically acceptable salt thereof wherein, R<1> represents halogen; R<2> and R<3> represent each independently hydrogen or halogen; R<4> represents hydrogen, halogen, lower alkyl, alkoxy or alkylmercapto; and R<5> represents hydrogen or lower alkyl. The compound (I) and salt thereof have an aldose reductase inhibitor activity against mammals including human and is excellent in safety. Therefore they are useful as remedies for treating complications of diabetes, such as defective union of injured cornea, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis. <CHEM>
Patent AU-532110-B2 (AU)
Title: Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
Inventor: BRITTAIN DAVID ROBERT
IPC: C07D487/04
Filed: 1980-10-29
Granted: 1983-09-15
Abstract: The invention concerns novel 1'-substituted spiro[imidazolidine-4,3'-indoline]-2,2',5-triones of the formula: <IMAGE> I  in which R1 is (1-12C)alkyl; phenyl, naphthylmethyl or cinnamyl optionally bearing 1-2 halogeno substituents; or benzyl optionally bearing 1-3 substituents independently selected from halogeno, trifluoromethyl, (1-4C)-alkyl, (1-4C)alkoxy, nitro, cyano and hydroxy; and ring A optionally bears one substituent selected from halogeno, (1-4C)alkyl, (1-4C)alkoxy, nitro and hydroxy, or two substituents independently selected from halogeno (1-4C)alkyl and nitro; or a pharmaceutically acceptable salt thereof; but excluding those compounds wherein R1 is methyl, ethyl, n-propyl or unsubstituted benzyl and benzene ring A is unsubstituted. The compounds of the invention are potent inhibitors of the enzyme aldose reductase and are of use in the treatment or prophylaxis of certain complications of diabetes or galactosemia. The invention also embraces processes for the manufacture of the novel compounds of formula I, as well as pharmaceutical compositions of such compounds. A representative compound is 1'-(2-fluoro-4-bromobenzyl)-spiro]imidazolidine-4,3'-indoline]-2,2',5- trione.
Patent AU-690038-B2 (AU)
Title: Balloon catheter with delivery side holes
Inventor: KUPIECKI DAVID
IPC: A61M29/02
Filed: 1996-10-08
Granted: 1998-04-09
Abstract: This is a medical catheter made up of a body having on its distal end portion an expandable balloon and, proximal of the balloon, a delivery lumen ending in a port through which therapeutic or diagnostic agents may be delivered. In one variation, a single inflation/wire lumen extends from the catheter proximal end to the catheter distal end, through which the balloon is inflated with pressurized fluid and through which a guide wire extends. The guide wire may have a valve plug for selectively seating against a valve seat of the catheter distal end to seal the inflation/wire lumen for balloon inflations. In another variation, a vaso-occlusive agent is disposable within a delivery lumen in a catheter coupled with a steerable guidewire. The delivery lumen ends in a delivery port near to and proximal of an expandable balloon located at the catheter's end. A single inflation/wire lumen may also be provided for facilitating both balloon inflation and guide wire tracking. <IMAGE>   <IMAGE>
Patent AU-638304-B2 (AU)
Title: Hepatitis c assay
IPC: G01N33/569
Filed: 1990-12-21
Granted: 1993-06-24
Abstract: The present invention provides an improved assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with polypeptide containing at least one epitope of an HCV antigen. Preferred assay formats include a confirmatory assay, a combination assay, a synthetic polypeptide-based assay, an immunodot assay, and a competition assay.
Patent AU-641457-B2 (AU)
Title: A construction for supporting a flexible sheet
Inventor: PICK WILLIAM E
IPC: B03C3/155
Filed: 1990-11-23
Granted: 1993-09-23
Abstract: A construction for supporting a flexible sheet is disclosed which includes a U-shaped channel having opposing flanges that are adapted to receive a complimentary spline member for frictionally engaging a flexible sheet, such as window screen, between a surface of the spline member and an adjacent inner surface of one flange of the U-shaped channel. The structure has several practical applications including the construction of window screens, electrostatic air filters of the charged media type, storm windows of plastic film and the like. An improved construction for an electrostatic air filter of the charged media type is also disclosed.
Patent AU-679765-B2 (AU)
Title: Isoquinoline derivatives as therapeutic agents
Inventor: SARGENT BRUCE JEREMY
IPC: C07D217/04
Filed: 1994-06-10
Granted: 1997-07-10
Abstract: PCT No. PCT/EP94/01926 Sec. 371 Date Dec. 21, 1995 Sec. 102(e) Date Dec. 21, 1995 PCT Filed Jun. 10, 1994 PCT Pub. No. WO95/00489 PCT Pub. Date Jan. 5, 1995Tetrahydroisoquinoline compounds of formula I    <IMAGE>  I  and pharmaceutically acceptable salts thereof, in which: R1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkyl-sulphonyl, nitro, cyano, polyhaloalkyl, polyhaloalkoxy, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), or R1 is optionally alkylated carbamoyl; R2 represents a saturated or unsaturated aliphatic group optionally substituted by hydroxy or alkoxy; E represents an alkylene chain optionally substituted by one or more alkyl groups; and G represents (a) optionally substituted saturated or unsaturated alicyclic group containing 3 to 8 carbon atoms, or (b) optionally substituted saturated or unsaturated aliphatic chain containing 1 to 12 carbon atoms, or (c) optionally substituted 5 or 6 membered heterocyclic ring containing one or more N or O atoms or SOn groups in which n is 0, 1 or 2; and O-acylated derivatives thereof which provide lipophilic esters have utility in analgesia or in the treatment of psychoses (e.g. schizophrenia), Parkinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.